Eita Sasaki

Has grant

National Institute of Infectious Diseases

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Immunology Immunology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Development of a novel adjuvant for vaccine against COVID-19 infection

Open Date: 2021-04-01

Close Date: 2022-03-01

Grant: Close

Identification and functional elucidation of a novel dendritic cell subset that induces efficient IgA production by nasal vaccine

Open Date: 2020-04-01

Close Date: 2023-03-31

Grant: Close

アジュバントのin vitro安全性・有効性ハイスループットスクリーニング系の創出を目指した研究

Open Date: 2017-04-01

Close Date: 2020-03-31

Grant: Close

Establishment of in vitro evaluation system for vaccine and adjuvant safety

Open Date: 2017-04-01

Close Date: 2019-03-31

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (1)

Taishi Onodera

Chief

National Institute of Infectious Diseases

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eita Sasaki

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (11)

Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.

Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox.

Calboxyvinyl polymer adjuvant enhances respiratory iga responses through mucosal and systemic administration.

Repeated Omicron exposures redirect SARS-CoV-2–specific memory B cell evolution toward the latest variants

Systemically inoculated adjuvants stimulate pDC-dependent IgA response in local site.

An investigation and assessment of the muscle damage and inflammation at injection site of aluminum-adjuvanted vaccines in guinea pigs.

Impact of injection buffer volume to perform bronchoalveolar lavage fluid collection for isolating alveolar macrophages to investigate fine particle-induced IL-1α secretion.

Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses.

HTLV-1 targets human placental trophoblasts in seropositive pregnant women.

Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.

Pharmacodynamic and safety considerations for influenza vaccine and adjuvant design.

Collaborators (1)

Taishi Onodera

Make your next move.